Versor Investments LP Takes $364,000 Position in Agilent Technologies, Inc. $A

Key Points

• Versor Investments LP acquired 3,115 shares of Agilent Technologies, Inc., valued at approximately $364,000, marking their entry into the company's stock.
• CEO Padraig Mcdonnell sold 1,508 shares at an average price of $117.44, resulting in a 3.87% decrease in his total holdings in the company.
• Agilent Technologies reported an earnings per share (EPS) of $1.31 for the last quarter, exceeding estimates by $0.05 and showing a revenue increase of 6.0% year-over-year.

Versor Investments LP purchased a new stake in Agilent Technologies, Inc. (NYSE:A - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 3,115 shares of the medical research company's stock, valued at approximately $364,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Corient IA LLC acquired a new stake in shares of Agilent Technologies in the first quarter valued at approximately $292,000. Northwest & Ethical Investments L.P. raised its holdings in shares of Agilent Technologies by 14.1% in the first quarter. Northwest & Ethical Investments L.P. now owns 385,655 shares of the medical research company's stock valued at $45,114,000 after purchasing an additional 47,636 shares during the last quarter. Raymond James Financial Inc. raised its holdings in shares of Agilent Technologies by 2.8% in the first quarter. Raymond James Financial Inc. now owns 368,661 shares of the medical research company's stock valued at $43,126,000 after purchasing an additional 10,077 shares during the last quarter. Cresset Asset Management LLC raised its holdings in shares of Agilent Technologies by 10.5% in the first quarter. Cresset Asset Management LLC now owns 9,300 shares of the medical research company's stock valued at $1,088,000 after purchasing an additional 884 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Agilent Technologies by 1.1% in the first quarter. Dimensional Fund Advisors LP now owns 1,162,783 shares of the medical research company's stock valued at $136,012,000 after purchasing an additional 12,284 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on A. JPMorgan Chase & Co. lowered their price objective on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating on the stock in a report on Thursday, May 29th. Barclays lifted their price objective on shares of Agilent Technologies from $115.00 to $125.00 and gave the company an "equal weight" rating in a report on Tuesday, June 24th. Robert W. Baird lowered their price objective on shares of Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating on the stock in a report on Thursday, May 22nd. UBS Group decreased their target price on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a research note on Thursday, May 29th. Finally, Leerink Partners raised their target price on shares of Agilent Technologies to $135.00 and gave the company a "buy" rating in a research note on Friday, May 30th. Seven analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Agilent Technologies has an average rating of "Moderate Buy" and a consensus price target of $139.77.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of Agilent Technologies stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the transaction, the chief executive officer directly owned 37,448 shares of the company's stock, valued at $4,397,893.12. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Agilent Technologies Stock Performance

A stock traded down $2.8830 during midday trading on Monday, reaching $118.7470. 747,893 shares of the company were exchanged, compared to its average volume of 1,938,554. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.60. The business has a 50-day moving average price of $117.88 and a two-hundred day moving average price of $117.05. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84. The firm has a market capitalization of $33.73 billion, a price-to-earnings ratio of 29.32, a price-to-earnings-growth ratio of 3.69 and a beta of 1.22.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings data on Wednesday, May 28th. The medical research company reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.26 by $0.05. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The firm had revenue of $1.67 billion during the quarter, compared to analysts' expectations of $1.63 billion. During the same period in the previous year, the business posted $1.22 earnings per share. The company's revenue for the quarter was up 6.0% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.540-5.610 EPS. Q3 2025 guidance at 1.350-1.370 EPS. Equities research analysts forecast that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.